University of California

University of Southern California

Biovinc LLC

Ichiro Nishimura

Charles E McKenna

Akishige Hokugo

Frank Hallock Ebetino

Shuting Sun

Mark Walden Lundy

Patricia R Spilman

Keivan Sadrerafi

Mohammad Parvez Alam

Jesus Campagna

Naren Subbiah

Varghese John

Boris A Kashemirov

Eric T Richard

Kenzo Morinaga

Cortino Sukotjo

In various embodiments deformable nano-scale vehicles (DNV) are provided that are useful for the delivery of therapeutic agents. In certain embodiments the DNVs are capable of transdermal delivery and can additionally cross the blood-brain barrier.

Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery

Disclosed herein are methods and compositions for removing or displacing bisphosphonates in skeletal tissue.

Skeletal removal of bisphosphonates

In certain embodiments osteoadsorptive fluorogenic substrates of cathepsin K (or other proteases) are provided. Utilizing a bisphosphonate targeting moiety, the fluorogenic substrates provide effective bone-targeted protease sensor(s). In certain embodiments the 'probes' comprise cleavable fluorophore-quencher pair linked by a cathepsin K (or other protease) peptide substrate and tethered to a bisphosphonate. Unlike existing probes that are cleared within a few days in vivo, the probes described herein (e.g., OFS-1) allow for monitoring resorption over the course of longer time periods with a single dose.

Osteoadsorptive fluorogenic substrate of cathepsin k for imaging osteoclast activity and migration

The present invention provides a method of treatment to improve wound healing and to minimize/prevent abnormal scarring caused by tissue contraction and fibrosis formation by providing a specific gene, Wit 3.0 alpha and beta sequences that is differentially expressed in wounded oral mucosa cells, relative to their decreased expression in non-wounded oral mucosa cells. One aspect of the invention is a method to treat soft tissue wound using anti-sense nucleic acid technologies. Another aspect of the present invention is a method to treat soft tissue wound using sense nucleic acid technologies. These methods can employ a complimentary nucleic acid sequence that is greater than 85% identity to Wit 3.0 alpha and/or beta sequences or greater than 90% identity to the deduced amino acids thereof.

Wit 3.0, a novel gene to control soft tissue wound healing

Growing community of inventors

Venice, CA, United States of America

Ichiro Nishimura